In a regulatory filing, Procept BioRobotics (PRCT) disclosed that its director Frederic Moll bought 20K shares of common stock on August 13th in a total transaction size of $785K.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Buy Rating for PROCEPT BioRobotics: Growth Potential and Stability Amid Sales Beat and Improved Guidance
- Procept Biorobotics Reports Strong Q2 Growth Amid Challenges
- Procept Biorobotics Corp.’s Aquablation Therapy: A Promising Update for Prostate Cancer Treatment
- Procept BioRobotics price target lowered to $55 from $80 at Piper Sandler
- PROCEPT BioRobotics Reports Strong Q2 2025 Growth